CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Shilpa Pharma, Inc. v. Novartis Pharmaceuticals Corporation

1:21-cv-00558

Overview

Case Number 1:21-cv-00558
Filing Date 2021-04-20
Status Litigation filed
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:1 Patent Infringement
Jury Demand Plaintiff

Parties

Notice Only

Ascend Laboratories LLC Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Special Master

Sue L. Robinson NPE (Individual / Inventor)

Represented By

0 Attorneys Listed
No attorneys available

Counter Claimant

Novartis Pharmaceuticals Corporation Operating Company

Represented By

11 Attorneys Listed

Allyson Parks

Email: AParks@gibsondunn.com

Robert W. Trenchard

Email: rtrenchard@gibsondunn.com

Paul E. Torchia

Email: ptorchia@gibsondunn.com

Kyanna Sabanoglu

UNDELIVERABLE EMAIL 1/26/2022

Jane M. Love

Email: jlove@gibsondunn.com

Emily M. Whitcher

Email: ewhitcher@gibsondunn.com

David Glandorf

Email: dglandorf@gibsondunn.com

Alexandra M. Joyce

McCarter & English, LLP

Tel: +1 (302) 984-6392
Fax: +1 (302) 450-4235

Renaissance Centre, 405 N. King Street, 8th Floor

Aileen C. Huang

UNDELIVERABLE EMAIL 3/15/2023

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Andrew Philip Blythe

Email: ablythe@gibsondunn.com

Counter Defendant

Individual A NPE (Individual / Inventor)

Represented By

0 Attorneys Listed
No attorneys available

Akshay Kant Chaturvedi NPE (Individual / Inventor)

Represented By

0 Attorneys Listed
No attorneys available

Prashant Purohit NPE (Individual / Inventor)

Represented By

0 Attorneys Listed
No attorneys available

Vinod Kumar Singh NPE (Individual / Inventor)

Represented By

0 Attorneys Listed
No attorneys available

Veereshappa Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Vimal Kumar Shrawat NPE (Individual / Inventor)

Represented By

0 Attorneys Listed
No attorneys available

Shilpa Medicare Limited NPE (University / Research)

Represented By

1 Attorneys Listed

Neal C. Belgam

Smith, Katzenstein, & Jenkins LLP

Tel: +1 (302) 652-8400

1000 West Street, Suite 1501, Wilmington, DE 19801

Shilpa Pharma, Inc. Operating Company

Represented By

9 Attorneys Listed

John T. Callahan

Email: jcallahan@sughrue.com

Daniel Taylor

Smith, Katzenstein & Jenkins LLP

Tel: +1 (302) 504-1681

1000 N. West Street, PO Box 410

Brett S. Sylvester

Email: bsylvester@sughrue.com

Raja N. Saliba

Email: rsaliba@sughrue.com

Michael R. Dzwonczyk

Email: mdzwonczyk@sughrue.com

Lawrence R. Rachuba

Email: lrachuba@sughrue.com

Eve H. Ormerod

Smith, Katzenstein, & Jenkins LLP

Tel: +1 (302) 652-8400
Fax: +1 (302) 652-8405

1000 West Street, Suite 1501, Wilmington, DE 19801

Chidambaram S. Iyer

Email: ciyer@sughrue.com

Neal C. Belgam

Smith, Katzenstein, & Jenkins LLP

Tel: +1 (302) 652-8400

1000 West Street, Suite 1501, Wilmington, DE 19801

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 2 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials 1 proceeding
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (2): 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (1 found):
PTAB: 1
USPTO PTAB Trial 2022-04-20
IPR2022-00886

Novartis Pharmaceuticals Corporation v. Shilpa Pharma, Inc.

Asserted Patent
Status: Final Written Decision
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US9266816
Fingolimod polymorphs and their processes
Filed: 2011-08-29
Issued: 2016-02-23
Active (4.8 yrs remaining)
Expires: 2031-08-29

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Active Threat

Active Threat — Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

72

Dispositive

12

Granted

3

Denied

2

Pending / Review

49

Motions by Category

Procedural / Extension Motion 37 Claim Construction / Markman Filing 21 Motion to Dismiss 12 Motion to Compel Discovery 2

Key Dispositive Motions & Rulings

Motion to Dismiss Granted
Minute Entry for proceedings held before Judge Maryellen Noreika - Discovery Dispute Telephone Conference held on 11/14/2022 regarding the issues presented in t...
Entry #— • 2022-11-14
Motion to Dismiss Pending / Under Review
REQUEST for Oral Argument by Shilpa Pharma, Inc. re 118 MOTION to Dismiss Counterclaim III of Novartis' Amended Answer and Counterclaims. (Ormerod, Eve) (Entere...
Entry #145 • 2022-06-30 Document →
Motion to Dismiss Pending / Under Review
REPLY BRIEF re 118 MOTION to Dismiss Counterclaim III of Novartis' Amended Answer and Counterclaims filed by Shilpa Pharma, Inc.. (Attachments: # 1 Exhibit 10, ...
Entry #142 • 2022-06-23 Document →
Motion to Dismiss Pending / Under Review
ANSWERING BRIEF in Opposition re 118 MOTION to Dismiss Counterclaim III of Novartis' Amended Answer and Counterclaims filed by Novartis Pharmaceuticals Corporat...
Entry #135 • 2022-06-16 Document →
Motion to Dismiss Denied
ORAL ORDER re 129 Stipulation and Order to Extend Time Regarding Motion to Dismiss Briefing - IT IS HEREBY ORDERED that the stipulation is DENIED. Additionally,...
Entry #130 • 2022-06-09 Document →
Motion to Dismiss Denied
STIPULATION and [Proposed] Order to Extend Time Regarding Motion to Dismiss Briefing by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 06/06...
Entry #129 • 2022-06-06 Document →

Docket Entries

(491 total)
Pleading / Complaint

COMPLAINT filed with Jury Demand against Novartis Pharmaceuticals Corporation - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3597638.) - filed by Shilpa Pharma, Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(apk) (Entered: 04/21/2021)

Entry #1 • 2021-04-21
1
Pleading / Complaint

COMPLAINT filed with Jury Demand against Novartis Pharmaceuticals Corporation - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3597638.) - filed by Shilpa Pharma, Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(apk) (Entered: 04/21/2021)

Entry #1 • 2021-04-21
2
Pleading / Complaint

COMPLAINT filed with Jury Demand against Novartis Pharmaceuticals Corporation - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3597638.) - filed by Shilpa Pharma, Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(apk) (Entered: 04/21/2021)

Entry #1 • 2021-04-21
2

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (apk) (Entered: 04/21/2021)

Entry #2 • 2021-04-21
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,266,816. (apk) (Main Document 3 replaced on 4/21/2021) (apk). (Entered: 04/21/2021)

Entry #3 • 2021-04-21
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc